Back to top
more

Supernus Pharmaceuticals, Inc. (SUPN)

(Delayed Data from NSDQ)

$29.45 USD

29.45
680,629

-1.49 (-4.82%)

Updated Feb 25, 2021 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 34% (168 out of 253)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Company News for Dec 24, 2020

Companies in the news are: SUPN, PLTR, JAGX, SRNE

Is Supernus Pharmaceuticals (SUPN) a Worthy Stock Now?

Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.

Company News for Nov 5, 2020

Companies In The News Are: CLH, HLT, RDWR, SUPN

Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Surpass Estimates

Supernus (SUPN) delivered earnings and revenue surprises of 174.07% and 18.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Beats Q2 Earnings and Revenue Estimates

Supernus (SUPN) delivered earnings and revenue surprises of 85.71% and 0.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Supernus (SUPN) This Earnings Season?

Supernus (SUPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Bionano (BNGO) to Report Q2 Earnings: What's in the Offing?

Bionano's (BNGO) sales numbers will be in focus when it reports Q2 results later in the week.

Bausch (BHC) Q2 Earnings & Revenues Miss Estimates, Down Y/Y

Bausch (BHC) misses on earnings and sales in the second quarter and announces plans to spin off its eye care division.

Endo (ENDP) Q2 Earnings & Sales Beat as Coronavirus Impacts Ease

Endo's (ENDP) earnings and sales beat estimates in the second quarter as COVID-19-related restrictions ease out.

Mallinckrodt's (MNK) Q2 Earnings & Sales Surpass Estimates

Mallinckrodt (MNK) declines on the news of a possible bankruptcy even though sales and earnings beat expectations in the second quarter.

Will Supernus (SUPN) Beat Estimates Again in Its Next Earnings Report?

Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q2 Earnings Expected to Decline

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Indrajit Bandyopadhyay headshot

Uncertainty Looms Large Over Generic Drug Industry Players

Stabilizing prices of generic drugs lead to recovery in the industry. New launches also provide a boost. However, coronavirus crisis creates an uncertainty for the industry.

Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Top Estimates

Supernus (SUPN) delivered earnings and revenue surprises of 33.33% and 11.47%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Supernus Pharmaceuticals (SUPN) Q4 Earnings Beat Estimates

Supernus (SUPN) delivered earnings and revenue surprises of 8.77% and -6.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Can Value Investors Pick Supernus Pharmaceuticals (SUPN) Stock?

Is Supernus Pharmaceuticals (SUPN) a great pick from the value investor's perspective right now? Read on to know more.

Supernus Pharmaceuticals (SUPN) Q3 Earnings and Revenues Lag Estimates

Supernus (SUPN) delivered earnings and revenue surprises of -8.47% and -6.51%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Supernus Pharmaceuticals (SUPN) Reports Next Week: Wall Street Expects Earnings Growth

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Value Investors Pick Supernus Pharmaceuticals (SUPN)?

Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.

Supernus Pharmaceuticals (SUPN) Q2 Earnings Top Estimates

Supernus (SUPN) delivered earnings and revenue surprises of 8.93% and -3.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Christopher Vargas headshot

4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal

In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.

Supernus Pharmaceuticals (SUPN) Lags Q1 Earnings and Revenue Estimates

Supernus (SUPN) delivered earnings and revenue surprises of -22.73% and -18.09%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Supernus' ADHD Candidate Positive in 4th Phase III Study

Supernus (SUPN) releases top-line results from the fourth phase III study on SPN-812 for the treatment of attention deficit hyperactivity disorder.